share_log

OneMedNet Completes Business Combination With Data Knights Acquisition Corp. to Become a Publicly Traded Company

OneMedNet Completes Business Combination With Data Knights Acquisition Corp. to Become a Publicly Traded Company

OneMedNet 與 Data Knights 收購公司完成業務合併,成爲一家上市公司
Accesswire ·  2023/11/08 03:00

OneMedNet Common Stock to Trade on Nasdaq Under Ticker "ONMD" Tomorrow, Wednesday, November 8, 2023

OnemedNet普通股將於明天,即2023年11月8日星期三在納斯達克上市,股票代碼爲 “ONMD”

OneMedNet to Fully Embark on its Growth Strategy as it Spearheads the Imaging RWD Solution in the $400 Billion Clinical Market

OneMedNet將全面啓動其增長戰略,在4000億美元的臨床市場中率先推出成像 RWD 解決方案

MINNEAPOLIS, MN / ACCESSWIRE / November 7, 2023 / OneMedNet Corporation (NASDAQ:DKDCA)(NASDAQ:DKDCW) ("OneMedNet" or the "Company"), the leading curator of regulatory-grade Imaging Real World Data ("RWD"), through its proven OneMedNet iRWD solution, today announced that it has completed its previously announced business combination with Data Knights Acquisition Corp. ("Data Knights"). The business combination was approved at a special meeting of Data Knights' stockholders and the combined company now operates as OneMedNet Corporation ("OneMedNet"). Beginning tomorrow, November 8, 2023, OneMedNet's shares of common stock and warrants will trade on the Nasdaq Stock Exchange under the ticker symbols "ONMD" and "ONMDW", respectively.

明尼蘇達州明尼阿波利斯/ACCESSWIRE/2023 年 11 月 監管級影像真實世界數據(“RWD”)的領先策展人OneMedNet Corporation(納斯達克股票代碼:DKDCA)(納斯達克股票代碼:DKDCW)(“OnemedNet” 或 “公司”)通過其久經考驗的OnemedNet iRwd解決方案今天宣佈,它已經完成了先前宣佈的與Data Knights Acquisition Corp.(“Data Knights”)的業務合併。業務合併在Data Knights股東特別會議上獲得批准,合併後的公司現在以OnemedNet Corporation(“OneMedNet”)的名義運營。從明天,即2023年11月8日開始,OnemedNet的普通股和認股權證將在納斯達克證券交易所上市,股票代碼分別爲 “ONMD” 和 “ONMDW”。

Paul Casey, OneMedNet's current Chief Executive Officer will continue to lead OneMedNet's current management team along with Aaron Green, as President, and OneMedNet's founder, Dr. Jeffrey Yu, as Chairman and Chief Medical Officer.

OnemedNet現任首席執行官保羅·凱西將繼續領導OneMedNet現任管理團隊,亞倫·格林將擔任總裁,OneMedNet創始人餘傑弗裏博士將擔任董事長兼首席醫療官。

"Today marks an historic achievement in OneMedNet's evolution as we become a publicly traded entity," commented Paul Casey, Chief Executive Officer of OneMedNet. "Reaching this milestone represents a strong step forward for OneMedNet. The finalization of the merger with Data Knights is a direct testament to the diligence and hard work of the collective teams and the continued acknowledgement of OneMedNet's unique and innovative regulatory grade iRWDTM data solution which supplies the life sciences industry with an actionable component to earlier detection and monitoring in the discovery of therapeutics and treatments. The Company has made significant strides in product and innovation capabilities and formed a solid operating structure required to effectively accelerate our growth strategy, including expanding our network through our active pipeline of partnership opportunities, and expanding OneMedNet's team to include leading industry talent. The $400 billion market of clinical research and clinical trials is a minimally penetrated greenfield opportunity for the Company and serves as a sustainable and ongoing competitive advantage to accelerate our growth and ultimately unlock value for all of our stakeholders."

OneMedNet首席執行官保羅·凱西評論說:“隨着我們成爲一家上市實體,今天標誌着OneMedNet的發展取得了歷史性成就。”“達到這一里程碑代表着OneMedNet向前邁出的堅實一步。與Data Knights的合併的最終完成直接證明了集體團隊的勤奮和辛勤工作,也證明了OneMedNet獨特而創新的監管等級iRWD的持續認可。TM 數據解決方案爲生命科學行業提供了可操作的組成部分,以便在發現療法和治療時進行早期檢測和監測。該公司在產品和創新能力方面取得了長足的進步,並形成了有效加快我們增長戰略所需的堅實運營結構,包括通過我們積極的合作機會擴大我們的網絡,以及擴大OneMedNet的團隊以包括行業領先人才。4000億美元的臨床研究和臨床試驗市場對公司來說是一個滲透率最低的新領域機會,也是加速我們的增長並最終爲所有利益相關者釋放價值的可持續和持續的競爭優勢。”

Barry Anderson, Chief Executive Officer of Data Knights added, "We are encouraged to have officially completed the combination with OneMedNet and confident in OneMedNet's position as the leading curator and the only provider of regulatory grade imaging iRWDTM on demand to drive its growth objectives. We reinforce our conviction of selecting OneMedNet as our partner in the formation of this combined company as its vanguard imaging data technology and diverse pipeline is poised to disrupt and transform healthcare data options for the discovery of impactful treatments in a variety of untreatable chronic illnesses. OneMedNet's iRWD solution is a game-changer for the life sciences industry with a clear trajectory to achieve rapid growth."

Data Knights首席執行官巴里·安德森補充說:“我們很高興正式完成了與OneMedNet的合併,並對OneMedNet作爲領先策展人和唯一監管級成像提供商(iRWD)的地位充滿信心TM 按需推動其增長目標。我們堅信選擇OnemedNet作爲我們的合作伙伴來組建這家合併後的公司,因爲其先進的成像數據技術和多樣化的產品線有望顛覆和改變醫療保健數據選擇,以發現各種無法治癒的慢性病的有影響力的治療方法。OneMedNet的iRWD解決方案改變了生命科學行業的遊戲規則,爲實現快速增長鋪平了道路。”

OneMedNet's innovation solutions connect healthcare providers and patients, offering direct access to clinical images and associated contextual patient record. OneMedNet proved the commercial and regulatory viability of imaging RWD, a promising emerging market, and provides regulatory-grade image-centric RWD that exactly matches OneMedNet's Life Science Partners' Case Selection Protocol. With a growing federated network of 200+ healthcare systems and providers, OneMedNet has the immediate ability to search and extensively curate multi-layer data from a Federated group of healthcare facilities quickly and proficiently.

OneMedNet 的創新解決方案將醫療保健提供者和患者聯繫起來,提供對臨床圖像和相關情境患者記錄的直接訪問。OneMedNet證明了成像RWD的商業和監管可行性,這是一個前景廣闊的新興市場,並提供了與OneMedNet生命科學合作伙伴的案例選擇協議完全匹配的監管級以圖像爲中心的RWD。隨着由200多個醫療保健系統和提供商組成的聯合網絡不斷壯大,OneMedNet能夠立即快速而熟練地搜索和廣泛整理來自聯邦醫療機構組的多層數據。

Advisors

顧問

ARC Group Ltd. acted as financial advisor and capital markets advisor to Data Knights Acquisition Corp. EF Hutton, a division of Benchmark Investments, LLC is acting as capital markets advisor.

ARC Group Ltd.曾擔任Benchmark Investments, LLC旗下的Data Knights收購公司的財務顧問和資本市場顧問EF Hutton擔任資本市場顧問。

Rimon P.C. acted as legal counsel to OneMedNet Corporation. Nelson Mullins LLP acted as legal counsel to Data Knights Acquisition Corp.

Rimon P.C. 擔任OneMedNet Corporation的法律顧問。納爾遜·穆林斯律師事務所擔任數據騎士收購公司的法律顧問

About OneMedNet Corporation

關於 OnemedNet 公司

Founded in 2009, OneMedNet provides innovative solutions that unlock the significant value contained within the clinical image archives of healthcare providers. Employing its proven OneMedNet iRWD solution, OneMedNet securely de-identifies, searches, and curates a data archive locally, bringing a wealth of internal and third-party research opportunities to providers. By leveraging this extensive federated provider network, together with industry leading technology and in-house clinical expertise, OneMedNet successfully meets the most rigorous RWD Life Science requirements. For more information, please visit .

OneMedNet成立於2009年,提供創新的解決方案,釋放醫療保健提供者臨床圖像檔案中包含的巨大價值。OneMedNet 採用其久經考驗的 OneMedNet iRWD 解決方案,可在本地安全地進行去身份識別、搜索和整理數據檔案,爲提供商帶來豐富的內部和第三方研究機會。通過利用這個廣泛的聯合提供商網絡,以及行業領先的技術和內部臨床專業知識,OneMedNet成功地滿足了最嚴格的 RWD 生命科學要求。欲了解更多信息,請訪問。

About Data Knights Acquisition Corp.

關於數據騎士收購公司

Data Knights Acquisition Corp. is a blank check company formed for the purposes of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more tech or software businesses or entities.

Data Knights Acquisition Corp. 是一家空白支票公司,其成立目的是與一家或多家科技或軟件企業或實體進行合併、資本證券交易、資產收購、股票購買、重組或類似的業務合併。

Safe Harbor Statement

安全港聲明

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

本新聞稿包含前瞻性陳述。此外,我們或我們的代表可能會不時以口頭或書面形式發表前瞻性陳述。我們將這些前瞻性陳述建立在我們對未來事件的預期和預測的基礎上,這些預期和預測來自我們目前獲得的信息。此類前瞻性陳述與未來事件或我們的未來表現有關,包括:我們的財務業績和預測;我們的收入和收益增長;以及我們的業務前景和機會。您可以識別那些非歷史性陳述的前瞻性陳述,尤其是那些使用 “可能”、“應該”、“期望”、“預期”、“考慮”、“估計”、“相信”、“計劃”、“預測”、“預測”、“潛力” 或 “希望” 等術語或這些術語或類似術語的否定詞的陳述。在評估這些前瞻性陳述時,您應該考慮各種因素,包括:我們改變公司方向的能力;我們跟上新技術和不斷變化的市場需求的能力;以及我們業務的競爭環境。這些因素和其他因素可能導致我們的實際業績與任何前瞻性陳述存在重大差異。前瞻性陳述只是預測。本新聞稿中討論的前瞻性事件以及我們或我們的代表不時發表的其他陳述可能不會發生,實際事件和結果可能存在重大差異,並受有關我們的風險、不確定性和假設的影響。我們沒有義務公開更新或修改任何前瞻性陳述,無論是由於不確定性和假設,本新聞稿中討論的前瞻性事件以及我們或我們的代表不時發表的其他陳述都可能不會發生。

Investor Contact:

投資者聯繫人:

Shannon Devine
MZ Group North America
203-741-8811
ONMD@mzgroup.us

香農迪瓦恩
MZ 集團北美
203-741-8811
ONMD@mzgroup.us

Company Contact:

公司聯繫人:

OneMedNet Corporation
Phone: 800.918.7189

OneMedNet 公司
電話:800.918.7189

Attn: Paul Casey, CEO
Email: paul.casey@onemednet.com

收件人:首席執行官保羅·凱西
電子郵件:paul.casey@onemednet.com

SOURCE: ONEMEDNET CORP.

來源: ONEMEDNET CORP.


View source version on accesswire.com:
在 accesswire.com 上查看源代碼版本:

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論